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Background: According to the World Alzheimer Report (Prince, The Global Impact of Dementia: an Analysis of
Prevalence, Incidence, Cost and Trends, 2015), 46.8 million people worldwide are nowadays living with dementia.
And this number is estimated to approximate 131.5 million by 2050, with an increasing burden on society and
families. The lack of medical treatments able to stop or slow down the course of the disease has moved the focus
of interest toward the nonpharmacological approach and psychosocial therapies for people with/at risk of dementia,
as in the Mild Cognitive Impairment (MCI) condition. The purpose of the present study is to test an individualized
home-based multidimensional program aimed at enhancing the continuum of care for MCI and outpatients with
dementia in early stage using technology.
Methods: The proposed study is a single blind randomized controlled trial (RCT) involving 30 subjects with MCI
and Alzheimer’s disease (AD) randomly assigned to the intervention group (Ability group), who will receive the
“Ability Program”, or to the active control group (ACG), who will receive “Treatment As Usual” (TAU). The protocol
provides for three steps of assessment: at the baseline (T_0), after treatment, (T_1) and at follow-up (T_2) with a
multidimensional evaluation battery including cognitive functioning, behavioral, functional, and quality of life
measures. The Ability Program lasts 6 weeks, comprises tablet-delivered cognitive (5 days/week) and physical
activities (7 days/week) combined with a set of devices for the measurement and monitoring from remote of vital and
physical health parameters. The TAU equally lasts 6 weeks and includes paper and pencil cognitive activities (5 days/
week), with clinician’s prescription to perform physical exercise every day and to monitor selected vital parameters.
(Continued on next page)* Correspondence: fbaglio@dongnocchi.it
2IRCCS, Fondazione don Carlo Gnocchi ONLUS, Via Capecelatro 66, 20148
Milan, Italy
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Realdon et al. BMC Psychiatry  (2016) 16:425 Page 2 of 9(Continued from previous page)
Discussion: Results of this study will inform on the efficacy of a technology-enhanced home care service to preserve
cognitive and motor levels of functioning in MCI and AD, in order to slow down their loss of autonomy in daily life.
The expected outcome is to ensure the continuity of care from clinical practice to the patient’s home, enabling also
cost effectiveness and the empowerment of patient and caregiver in the care process, positively impacting on their
quality of life.
Trial registration: ClinicalTrials.gov ID: NCT02746484 (registration date: 12/apr/2016 – retrospectively registered).
Keywords: Telerehabilitation, Dementia, Mild cognitive impairment, Alzheimer’s disease, Continuum of careBackground
Dementia is now considered as a social emergency since
it became one of the 25 main causes of disability in
people worldwide over the last few decades [25]. De-
mentia affects multiple domains, such as cognitive func-
tioning, behavioral aspects and functional skills. It has
also a significant impact on personal autonomy in daily
life and social relationships, associated to a high level of
caregiver burden as indicated by data from 2015 World
Alzheimer Report [28]. The most common form of de-
mentia is Alzheimer’s disease (AD), a progressive neuro-
degenerative condition accounting for up to 60% of all
dementia cases [38]. From the clinical and health man-
agement point of view, Mild Cognitive Impairment
(MCI) and early stages of AD represent the most inter-
esting clinical conditions. MCI is considered a condition
at risk for the development of dementia, therefore early
interventions can be essential to prevent or delay further
decline. Currently, no pharmacological therapies are
available to prevent a potential conversion from MCI to
AD condition or to change the AD course. However, dif-
ferent types of non pharmacological interventions have
been developed and an increasing body of evidence
shows that cognitive stimulation programs bring benefits
to cognitive function of people with mild to moderate
dementia over and above any medication effects [6, 39].
Within the framework of non pharmacological interven-
tions, the use of technology to assist the person at risk
and/or with mild dementia at home and to extend re-
habilitation services in the treatment of dementia has
gradually gained importance. It provides a range of
home services based on innovative technologies which
include therapeutic interventions, remote monitoring of
progress and training for caregivers of people with dis-
ability [18]. These long-distance rehabilitation services
were primarily developed in order to provide equitable
access to local sanitary systems for individuals who are
geographically remote or with physical disabilities for
whom it is difficult to reach the hospital [35]. Nowadays,
as long as the potential benefits of telerehabilitation have
been highlighted in the literature [2], these technologies
are also being applied to cognitive rehabilitation. In fact,
unlike usual face-to-face care rehabilitation protocols,these technological approaches appear to be more
advantageous in terms of intensity and duration of treat-
ment, lowest costs and support of dyad (patient and
caregiver) at home [11, 20].
Nonetheless, the efficiency and efficacy of home-based
technology-enhanced continuum of care programs are
poorly examined and evidences are controversial. More-
over, functional skills, level of patient engagement at home
and psychological well-being are under-investigated des-
pite their being key outcomes of interest [21]. Randomized
controlled trials (RCT) are strongly needed to determine
the optimal design of home-based treatment protocols
and identify their long-term benefits.
The main aim of the proposed trial is to test the per-
formance of a technology-enhanced rehabilitation and
telemonitoring program (The Ability Program) to ensure
the continuity of care from clinical setting to patient’s
home. We will investigate whether MCI and people with
early AD participating in the Ability program will show
improvements in cognition and quality of life (outcome
evaluation; efficacy) and better adherence and engage-
ment in the program (output evaluation; efficiency) with
respect to MCI and AD subjects taking part in the TAU.
Methods
Study design
The design is a single-blind, randomized, two-treatment
arms (Ability Program, over 6 weeks vs. TAU, over 6
weeks) controlled clinical trial. After enrollment and
baseline assessment, MCI and AD subjects will be ran-
domized (with an allocation ratio of 1:1) into either the
Ability group (30 motor-cognitive rehabilitation sessions
combined with the measurement and monitoring from
remote of vital parameters delivered at home through
the Ability platform) or the active control group (ACG)
(30 motor-cognitive rehabilitation sessions combined
with the measurement of vital parameters to be per-
formed at home through the usual care treatment pro-
cedure). Primary and secondary outcome measures will
be obtained at baseline (T_0) before starting either pro-
gram, post-intervention at 8 weeks after baseline (T_1)
and at follow up 12 months after baseline (T_2). Consol-
idated Standards Of Reporting Trials (CONSORT) flow
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TelerehABILITation study is showed in Fig. 1.Sample size
According to previous multicenter controlled studies [3,
14], sample size calculation was performed considering
that under the assumption of normal distribution of the
scores (primary outcomes differences between groups)
and considering α level of .05, a sample size of 30 sub-
jects resulted in a power greater than 70% and was
therefore considered as adequate for this trial. To avoid
loss to follow-up and maximize the follow-up sample,
standard procedures (regular phone contacts with partic-
ipants) will be applied.Participants
Thirty participants will be consecutively recruited from
the Memory Clinic of IRCCS Don Carlo Gnocchi
Foundation.Fig. 1 CONSORT flow diagram. Consolidated Standards Of Reporting Trials
TelerehABILITation studyOutpatients inclusion criteria will be the following:
a) diagnosis of mild AD or MCI due to AD, according
to DSM- 5 diagnostic criteria and AD/MCI diagnostic
criteria [23, 1]; b) MMSE score >18 (Mini Mental State
Examination, [15, 22]); c) aged over 65 years and d)
with school attendance ≥3 years.
Exclusion criteria will be a) severe auditory and/or vis-
ual loss; b) overt severe behavioral disturbances. and c)
recent (1 month or less before starting the program)
introduction or dose modification of the following
pharmacological treatments: cholinesterase inhibitor,
memantine, antidepressant, or antipsychotic drugs. Low-
dose benzodiazepines for insomnia will be allowed dur-
ing the study.
Randomization and masking
Randomization will occur after screening and baseline
assessments. Subjects will be randomly assigned to
the Ability group or to the ACG with a 1:1 allocation
ratio. Randomization will be conducted by an(CONSORT) flow diagram for enrollment and randomization in the
Table 1 Tablet-based cognitive activities
Main domain Activities: examples of contents
Language Reading and comprehension of a piece of
newspaper article
Word production from semantic category in a
specific time
Word production based on a specific letter
Word production based on a specific syllable
Word production from a semantic category,
based on a specific letter
Memory Recall of popular songs, films or actor’s biographies
Memorization of daily life notes or brief messages
and recall at the end of the cognitive session
Memorization of a list of words and recall, searching
for words which were not included in the list
previously stored
Recall of information in the newspaper article
previously read and answering questions about it
Carefully looking at a painting and memorizing
Recall of information from a painting previously
observed and answering some questions
Inclusion of correct missing words in the text of
some popular poems
Executive
function
Putting things in the correct sequence based on
a specific criterion
Putting actions of daily life in the correct sequence
Mathematical calculations
Anagrams
Rebuses (using pictures for words)
Labyrinths
Placing hands in empty clocks based on the
time indicated in arabic figures
Attention Finding specific words in a grid of mixed words
Finding a specific letter in a grid of mixed letters
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ment and/or treatment using a computer algorithm
(http://www.graphpad.com/quickcalcs/randMenu/). Since
participants cannot be blinded to their treatment alloca-
tion, they will be instructed not to discuss the nature of
their intervention with the researchers in charge of the as-
sessments. Outcome measures will be collected by re-
searchers blinded to group allocation.
Intervention
The study protocol predicts the random assignment
of all participants to the Ability Program or to the
TAU according to a single-blind parallel-group study
approach.
Both programs last six consecutive weeks and combine
cognitive and motor activities with the measurement of
vital parameters, all to be performed at home. According
to the Individual Rehabilitation Plan (IRP), the rehabili-
tation protocol in both programs comprises the per-
forming of cognitive exercises for 5 days a week and
light motor activities for 7 days a week. The selection of
vital parameters and frequency of their measurement is
set by the clinician, according to individual diagnosis.
The Ability program
The Ability program is a technology-enhanced version
of the home-based usual care program (TAU), with the
same duration, type of rehabilitation domains (motor
and cognitive), dose of respective rehabilitation sessions,
prescription for the monitoring of vital parameters, with
the addition of a tracking device for physical activity and
sleep, and monitoring from remote of all the activities
performed by the participant.
Subjects assigned to this group are provided with the
Ability kit, a set of technological devices including: a
tablet for the delivery of the IRP; a sphygmomanometer
for the detection of blood pressure; a pulse oximeter for
the measurement of oxygen blood level and heart rate; a
scale for the detection of body weight, and a FitBit
Charge to track physical and sleep activity.
For all the 6-week intervention, the IRP is delivered
through the tablet that, every day, after opening its user-
friendly dashboard, shows the activities planned by the
clinician for that day. Cognitive exercises are delivered
for 5 days a week, adapted motor activity is proposed for
3 days a week, while light aerobic motor activity is sug-
gested for the remaining 4 days. At least once a week a
message on the dashboard recalls subjects to measure
the vital parameters critical for their clinical condition,
according to medical prescription. As regards the FitBit
tracker, no tablet-based recalls are predicted since partic-
ipants are asked to wear it continuously (24 h) for all the
6 weeks, except for very short interruptions to recharge
it (about 2 hours once a week).Tablet-based cognitive and motor activities in the Ability
program
Tablet-based cognitive activities aim to reinforce mul-
tiple cognitive domains: attention, reasoning, procedural,
semantic and autobiographic memory, executive func-
tions, and visual-spatial skills (see Table 1). Activities
within each cognitive daily session are sequentially
framed in a way that they typically begin with a learning
phase in which several stimuli are proposed. Then, they
typically continue with activities that stimulate attention
and other cognitive functions. Finally, a recall task is
proposed. Each activity is structured into five levels of
difficulty that adaptively increase on the basis of subject’s
performance. The total time predicted for each daily
cognitive session is about 20 min.
Aerobic physical exercises are adapted motor activities
[13] that involve the performing of simple movements,
e.g., shoulder rotations, arm rotations, lower limb flexion,
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ported via video clips (see Fig. 2). Each activity starts with
a brief explanatory training conducted by the physiother-
apist that also shows the correct execution of the exer-
cises. Then the subject starts the movements mirroring
the therapist while watching the video. Soft background
music in time with the activity is played to improve the
synchronized movement pattern, to capture attention and
to foster engagement with the task [34]. Subjects use the
support of a chair in all activities, both for home safety
and since they often suffer from (sub) clinical balance
disturbances. The total time envisioned for each
adapted motor activity is about 15 min.
Before starting the program, participant and caregiver
dyads are invited at the Memory Clinic to collect the
Ability kit. On that occasion, they go through a training
session lasting approximately two hours. The training
that researchers will provide to participants and their
carers will focus both on familiarizing with the techno-
logical devices of the kit and on how to use them. After
a brief explanation of the functions of the several devices
of the kit, researchers will conduct the training with a
learning-by-doing experiential approach, scaffolding
dyads in the management, from beginning to end, of a
sample daily Ability session. The aim is to let patients
and their carers get a working knowledge of the techno-
logical devices of the kit, meant for them as interfaces
enabling their care experience, rather than focusing on
abstract explanations on the technologies at hand. The
participatory appropriation training starts with theFig. 2 Motor activities in the Ability Program. Tablet-delivered motor activi
the cervical spine, conducted by a physiotherapist and reported via video copening of the tablet, the familiarization phase with the
dashboard, and proceeds with a sample daily session of
cognitive activities. The sample session, specifically de-
vised for training purposes, includes at least one cognitive
activity within each type of the different implementation
designs developed. By implementation design we mean
the different actions (e.g., touching a blank space to let the
keyboard appear) that a user needs to do to operationalize
his intentions (e.g. write a word in a semantic fluency ac-
tivity) in order to reach the desidered goal. Dyads are in-
vited to operate by themselves on the tablet and, in case of
mistakes, an errorless approach will be adopted, in order
to encourage their sense of coherence and to empower
self-efficacy beliefs in following the tasks proposed. Then,
upon completion of the cognitive session, they will man-
age the transition back to the dashboard with the oppor-
tunity to either watch a video of an adapted motor activity
or go to the vital parameters measurement recall session,
in order to gain confidence in moving back and forth
within the platform. Whatever the route selected on
which to do first, they will then be invited to do the other,
so as to have the opportunity to manage video watching
through the tablet and to try the different vital parameters
measurement devices. At the end of the tablet session, re-
searchers will show the dyad the FitBit tracker that the
participant will have to wear. They will instruct him to
wear it day and night for all the 6 weeks of treatment, pro-
viding brief hints on its use. To wrap up all the informa-
tion shared, researchers will provide dyads with a manual
showing screenshots of all the basic tablet proceduresties in the Ability Program for the upper and lower arm, the trunk and
lips
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to use, to charge, or to wear the several devices of the kit.
Moreover, dyads will be informed that phone contacts are
planned during the 6 weeks of intervention, with the
opportunity of being called or to call themselves both a
Support Service Centre for technical problems (e.g. con-
nectivity) and a neuropsychologist as care manager.Treatment As Usual
The ACG will receive TAU, which, according to IRP,
comprises: a) paper and pencil cognitive activities to be
performed at home 5 days a week, covering the same
domains as the Ability Program (See Table 1), with five
levels of difficulty progressively increasing week by week
independently from participant’s performance the week
before; b) prescription to perform light aerobic motor
activity 7 days a week (e.g. walking for 30 min.); c) pre-
scription to measure specific vital parameters according
to individual clinical condition.
Before starting the program, the participant and carer
dyad are invited at the Memory Clinic to collect the
workbook containing paper and pencil cognitive
activities and written clinicians’ prescriptions about
motor activities and measurement of vital parameters.
Researchers will provide the dyad with a brief training
including instructions a) on the number of days per week
in which to perform the exercises, at the same time en-
couraging the respect for pause periods; b) on the need to
respect the dose of daily rehabilitation activities; c) on
how to manage down-motivating drawbacks (especially in
case of loss of perceived balance between skills and chal-
lenge in cognitive activities).Assessment design and outcomes measures
The timeline of the study is illustrated in Fig. 3. Assess-
ments will be done in both groups at baseline (T_0), atFig. 3 Timeline of the trial. Timing and duration of the various proceduresthe end of intervention, 8 weeks after baseline (T_1),
and at follow up, 12 months after baseline (T_2).
With respect to participants, we will adopt a multifa-
ceted evaluation approach including cognitive function-
ing, behavioral, functional and perceived quality of life
measures. Moreover we will also assess respective care-
givers’ perceived burden and psychological well-being.
Participants’ cognitive functioning will be assessed
through an extensive neuropsychological battery including:
 the Montreal Cognitive Assessment (MoCa; [9]), a
sensitive tool for general cognitive level assessment;
 the Free and Cued Selective Reminding Test
(FCSRT Delayed Free Recall (DFR) and Immediate
Free Recall (IFR); [16]) for long-term memory
evaluation;
 the Trail Making Test (TMT; [19]) for frontal-
executive functions
 the Verbal Fluencies [27] for the assessment of
language skills.
Participants’ functional and behavioral levels will be
evaluated through the following proxy measures:
 the Activities of Daily Living Inventory (ADCS/
ADL; [17])
 the Neuropsychiatric Inventory (NPI; [10]).
Both are proxy measures administered to caregivers.
Perceived participants’ quality of life (QoL) will be
assessed through:
 the Dementia Quality of Life Instrument (D-QoL;
[4]), a dementia-specific self-report measure
recommended by the European consensus on
outcome measures for non-pharmacological
interventions on dementia [24],in the trial design
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Brief Version (Brief-COPE; [7]), since coping skills
are considered as mediator variables for Quality of
Life outcomes.
The evaluation of perceived burden and quality of life
in caregivers will be done through:
 the Psychological Well-Being scale (PWB; [30, 31]);
 the Positive and Negative Affect Schedule (PANAS;
[37, 33]);
 the Coping Orientation for Problems Experienced –
Brief Version (Brief-COPE; [7, 32]);
 the Caregiver Burden Inventory (CBI; [26]).
Only participants in the Ability program group will be
also administered, at the end of the intervention (T_1),
the System Usability scale (SUS; [5]), in order to test
how the Ability platform’s usability is perceived.
As primary outcome measure we consider the QoL of
participants, being a measure of how a disease and its
treatment affect a person’s capability to develop everyday
activities and play valuable roles in their own life.
Improvement in QoL plays a key role for individuals
living with cognitive impairment, their family and carers.
Secondary outcome measures include specific cognitive
functioning such as memory, language and executive
functions, being those abilities more compromised in
MCI due to AD subjects [1], performance of complex
instrumental activities of daily living, behavioral symp-
toms, and rates of conversion in dementia (see previous
section).
Statistical analyses
Statistical analyses on outcome measures will be con-
ducted using SPSS. We will look at statistically significant
changes in primary and secondary outcome measures
from T_0 (start of treatment) to T_1 (end of treatment),
i.e. a training effect. Moreover, we will look for a treatment
(Ability vs. TAU) effect and at training x treatment inter-
actions. This will be done through a 2-way ANOVA. Post
hoc analysis will be applied to compare Ability with TAU.
An alpha ≤ 0.05 will be considered significant. Moreover,
score modification at T_2 (after 12 months) in both
groups will be evaluated by means of regression analyses
over time considering previous values at baseline and T_1.
Contributing factors that may predict changing in out-
comes will be also examined in a multivariate interval
regression analysis. Moreover, each outcome will be cate-
gorized in three intervals according to the criterion of a
clinical improvement/stability/impairment which was set
by expert physicians. Given the exploratory nature of the
study, a stepwise forward model will be set with an
entrance alpha level of 0.10. Model assumptions andgoodness of fit were evaluated by means of the pro-
portionality of odds across response categories test
and the association between predicted and observed
values (Spearman rho). When the proportionality of odds
assumption is violated, a generalized logistic regression
model will be computed. For each significant model, sev-
eral representative profiles and their associated probability
of a successful treatment will be computed.
Discussion and conclusions
In the framework of at home continuum of care pro-
grams, technologies have been increasingly conceived as
a support for patients, their carers and healthcare pro-
fessionals in the management of the disease. Increasing
access to care, reducing health care costs and promoting
the migration of care from medical institution to pa-
tient’s home are the principal aims of telerehabilitation
for people with chronic conditions [12, 29].
In this context [36], the present innovative protocol is
claiming to provide MCI subjects together with people
with AD and their caregivers with an innovative
technology-based program for the continuity of care in
their favorite and most familiar environment, adopting a
multidimensional rehabilitation approach including cogni-
tive and motor activities. In this protocol, the Ability pro-
gram is designed as an enhancement through technology
of the usual care program, enabling additional relevant
care options like scheduled delivery of the IRP, telemoni-
toring of vital parameters, and tracking of physical activity.
In order to minimize the lack of familiarity of elderly
people with technologies, the challenge is to identify and
to enhance individual factors that promote and facilitate
human-technology interaction, increasing the acceptance
of such an innovative and high-tech health care program
[11]. To reach this goal, it is important to shape the
intervention on the basis of user needs. As a novel tele-
health platform, Ability is designed and implemented
taking into account the patient’s age, education, interest,
physical condition, access to technology, functional inde-
pendence in daily life and the presence of supportive
caregivers.
We expect that everyday rehabilitative sessions may
have some positive effects on psychological and physical
well-being of people with cognitive impairment, redu-
cing cognitive and motor impairment and enhancing
their quality of life. In addition, the Ability program may
promote the continuity of care from clinical practice to
patient’s home: it may be a more advantageous system
for healthcare professionals, who have the opportunity
to support the rehabilitation process in the distance,
monitoring the progress and eventually changing the
rehabilitation plan in a flexible and easy way according
to a tailored intervention. The neurologist and the
neuropsychologist are provided with the opportunity to
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dedicated platform contacting patients when appropriate
(for example, in case of lack of compliance).
Caregivers can also have benefits from Ability program,
which may result in the enhancement of their subjective
perception of well-being and quality of life. We can
assume that it may be useful to prevent or to mitigate
caregiver burden by making the rehabilitation process eas-
ier to be carried out at home and by enhancing social
interaction with the patient during the performance of the
training program, promoting the quality of life of both pa-
tients and their caregivers through a joint engagement to
reach the rehabilitation target [8]. Finally, we want to test
the user experience of this program in elderly people, for
which this practice is still often unfamiliar [40].
In sum, we expect that the Ability program can be a
promising adaptive home-assistance service to contrast
AD progression, testing its outcome in terms of rehabili-
tation, user experience and quality of life of people with
MCI and early AD conditions and their carers.
Trial status
The trial is ongoing.
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